TABLE 3.

Drugs that can influence currently identified proteins associated with dementia, their potential mechanisms of action, and current indications

Protein	Medication	Action	Phase passed	Indications
CDCP1	Itolizumab 118	Prevents CDCP1 binding to CD6 and down regulates T cell activation and infiltration. It also reduces synthesis of pro‐inflammatory cytokines reducing T cell infiltration at sites of inflammation.	III	Psoriasis
NPS‐PLA2	Varespladib and Varespladib Methyl 117	Inhibits arachidonic acid pathway in inflammation by inhibiting NPS‐PLA2 activity and subsequent leukocyte activation.	III	Atherosclerotic cardiovascular diseases, inflammatory diseases, snake venom antidote
IGFBP‐7	Intranasal insulin, metformin, and GLP‐1 receptor agonists 113	Insulin nasal spray restores central insulin levels that may be downregulated by elevated IGFBP‐7 levels. Metformin acts as insulin sensitizer and GLP‐1 agonists stimulate insulin secretion.	III	Cognitive decline and Alzheimer´s disease
N‐terminal pro‐BNP	Antihypertensive medications 103	Reduce N‐terminal pro‐BNP levels in circulation by reducing atrial and ventricular overload.	III	Hypertension
OPG	Atorvastatin, metformin, pioglitazone, rosiglitazone 88 , 119 , 120	Reduce OPG levels possibly by reducing inflammation and by stabilizing atherosclerotic plaques.	III	Atherosclerotic cardiovascular diseases, diabetes
MIC‐1	Monoclonal antibody CTL‐002 121	Neutralizes MIC‐1	‐	Advanced cancer